Rifaximin Reduces the Risk of Hospitalizations in Patients with Previous Episodes of Hepatic Encephalopathy: Results from a Phase 3 Placebo-Controlled Trial

被引：0
|
作者：
Neff, Guy
Leevy, Carroll B.
Frederick, Todd
Merchant, Kunal
Huang, Shirley
Shaw, Audrey L.
Forbes, William P.
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A11 / A12
页数：2
相关论文
共 50 条
  • [1] SAFETY OF RIFAXIMIN IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A RANDOMIZED, PHASE 3, PLACEBO-CONTROLLED CLINICAL TRIAL
    Mullen, K.
    Sigal, S.
    Sheikh, M.
    Bass, N.
    Poordad, F.
    Merchant, K.
    Huang, S.
    Shaw, A.
    Bortey, E.
    Forbes, W.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S84 - S85
  • [2] RIFAXIMIN IS EFFECTIVE IN MAINTAINING REMISSION IN HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Bass, N.
    Mullen, K.
    Sigal, S.
    Sanyal, A.
    Poordad, F.
    Merchant, K.
    Huang, S.
    Shaw, A.
    Bortey, F.
    Forbes, W.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S39 - S39
  • [3] RIFAXIMIN TREATMENT IMPROVED QUALITY OF LIFE IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Sanyal, A.
    Bass, N.
    Mullen, K.
    Poordad, F.
    Shaw, A.
    Merchant, K.
    Bortey, E.
    Forbes, W. P.
    Huang, S.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S7 - S7
  • [4] RIFAXIMIN FOR THE PREVENTION OF HEPATIC ENCEPHALOPATHY IN PATIENTS TREATED BY TIPS : A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Bureau, Christophe
    Jezequel, Caroline
    Archambault, Isabelle
    Thabut, Dominique
    Dharancy, Sebastien
    Perarnau, Jean Marc
    Oberti, Frederic
    Borentain, Patrick
    Carrie, Nathalie Ganne
    Plessier, Aurelie
    Carbonell, Nicolas, Sr.
    Rousseau, Vanessa
    Sommet, Agnes
    Peron, Jean-Marie
    HEPATOLOGY, 2019, 70 : 10A - 10A
  • [5] Adalimumab reduces pain in patients with hidradenitis suppurativa: Results from a placebo-controlled phase II trial
    Kimball, Alexa B.
    Chen, Ke
    Okun, Martin
    Sundaram, Murali
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB42 - AB42
  • [6] Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)
    Patel, V.
    Mcphail, M. J. W.
    Zamalloa, A.
    Stoy, S.
    Vijay, G. M.
    Huang, X.
    Rogers, G.
    Choo, J.
    Edwards, L.
    Gray, E.
    Woodhouse, C.
    Gencer, S.
    Coen, M.
    Wendon, J.
    Bruce, K.
    Shawcross, D.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S107 - S108
  • [7] Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
    Bajaj, J. S.
    Barrett, A. C.
    Bortey, E.
    Paterson, C.
    Forbes, W. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (01) : 39 - 45
  • [8] Utility of the Hepatic Encephalopathy Scoring Algorithm (HESA) for Diagnosing Hepatic Encephalopathy in a Randomized, Controlled Trial of Rifaximin vs. Placebo
    Hassanein, Tarek
    Barakat, Fatma
    Barrett, Andrew C.
    Bortey, Enoch
    Paterson, Craig
    Forbes, William P.
    GASTROENTEROLOGY, 2013, 144 (05) : S997 - S998
  • [9] RIFAXIMIN IMPROVES DRIVING SIMULATOR PERFORMANCE IN MINIMAL HEPATIC ENCEPHALOPATHY: A DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE RANDOMIZED TRIAL
    Bajaj, Jasmohan S.
    Heuman, Douglas M.
    Saeian, Kia
    Hafeezullah, Muhammad
    Bell, Debulon E.
    Sterling, Richard K.
    Stravitz, R. Todd
    Wegelin, Jacob A.
    White, Melanie
    Sanyal, Arun J.
    HEPATOLOGY, 2010, 52 (04) : 330A - 330A
  • [10] RIFAXIMIN REDUCES HEALTHCARE UTILIZATION IN PATIENTS WITH CIRRHOSIS AND RECURRENT EPISODES OF HEPATIC ENCEPHALOPATHY: A RETROSPECTIVE EFFICACY STUDY
    Van Doorn, Diederick
    Van Eekhout, Kirsi
    De Wit, Koos
    Baak, Lubburtus C.
    Klemt-Kropp, Michael
    Verwer, Bart
    Friederich, Philip W.
    De Bruin, Gijs J.
    Vos, Xander
    Takkenberg, Bart
    HEPATOLOGY, 2023, 78 : S1410 - S1410
12345